Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities lawsuit

Unicycive Securities Fraud Class Action Over FDA CRL

Analysis based on 58 articles · First reported Sep 03, 2026 · Last updated Sep 22, 2026

Sentiment
-15
Attention
2
Articles
58
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The litigation and the underlying FDA Complete Response Letter have already driven a sharp decline in Unicycive's share price, and the pending class action adds legal and reputational overhang that could further pressure the stock and raise financing costs. Broader market impact is limited, as this is a single small-cap biotech issuer event with no systemic read-through beyond heightened scrutiny of FDA manufacturing-compliance disclosures in the sector.

pharmaceuticals biotechnology legal services

Multiple investor-rights law firms have filed or announced securities fraud class action lawsuits against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers on behalf of investors who acquired Unicycive securities between December 29, 2025 and June 29, 2026. The complaints allege that Unicycive made materially false and misleading statements and failed to disclose that it had not inspected its third-party manufacturing vendor's facility or audited the facility's compliance with current good manufacturing practices; that it therefore lacked a reasonable basis to believe the vendor had remedied deficiencies cited by the United States — Food and Drug Administration; that there was an undisclosed risk the FDA would require additional information about the vendor's manufacturing practices; and that regulatory approval of oxylanthanum carbonate was reasonably likely to be delayed. According to the complaints, on June 30, 2026, before market open, Unicycive disclosed that the FDA had issued a Complete Response Letter regarding its resubmitted New Drug Application for OLC, identifying the same third-party manufacturing deficiencies cited in a prior June 2025 CRL. On that news, Unicycive's stock reportedly fell $3.01, or 39.1%, to close at $4.69 per share on June 30, 2026. Bronstein, Gewirtz & Grossman, LLC, Glancy Prongay & Murray, The Law Offices of Frank R. Cruz, and the Law Offices of Howard G. Smith have each publicized the action and are soliciting investors. Investors have until November 2, 2026 to seek appointment as lead plaintiff.

stock
Unicycive is the defendant and central subject of the securities fraud class action, facing allegations of misleading investors about third-party manufacturing deficiencies and the resulting FDA Complete Response Letter for oxylanthanum carbonate. The stock reportedly fell 39.1% on the CRL disclosure, and the litigation adds legal costs and reputational damage.
Importance 100.0 Sentiment -70.0
govactor
The FDA issued the Complete Response Letter for Unicycive's resubmitted NDA for oxylanthanum carbonate, citing the same third-party manufacturing deficiencies as the prior June 2025 CRL, which triggered the stock decline and the lawsuits.
Importance 60.0 Sentiment 0.0
priv
Bronstein, Gewirtz & Grossman, LLC is one of the law firms announcing and soliciting investors for the securities fraud class action against Unicycive and its officers.
Importance 40.0 Sentiment 0.0
priv
Glancy Prongay & Murray filed a securities fraud lawsuit on behalf of Unicycive investors and is notifying potential class members of the lead plaintiff deadline.
Importance 35.0 Sentiment 0.0
priv
The Law Offices of Frank R. Cruz is reminding investors of the November 2, 2026 lead plaintiff deadline in the securities fraud class action against Unicycive.
Importance 35.0 Sentiment 0.0
per
As founding partner of the plaintiff law firm, Peretz Bronstein is leading the litigation effort, which could bring recognition and financial benefit to the firm.
Importance 30.0 Sentiment 10.0
per
Nathan Miller serves as client relations manager, facilitating investor participation in the class action, supporting the firm's case development.
Importance 20.0 Sentiment 10.0
govactor
The SEC is not directly involved in this private lawsuit, but the allegations of securities law violations could attract regulatory attention, potentially leading to an investigation.
Importance 10.0 Sentiment 0.0
Bronstein, Gewirtz & Grossman, LLC co-counsel ↔ Glancy Prongay & Murray Bronstein, Gewirtz & Grossman, LLC frequently acts as co-counsel with Glancy Prongay & Murray in various securities clas
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ The Law Offices of Frank R. Cruz Bronstein, Gewirtz & Grossman frequently acts as co-plaintiff with The Law Offices of Frank R. Cruz in securities class
Bronstein, Gewirtz & Grossman, LLC investor advocate ↔ United States — United States Securities and Exchange Commission Bronstein, Gewirtz & Grossman, LLC is a private law firm that represents investors in securities class action lawsuits,
Glancy Prongay & Murray co-counsel ↔ The Law Offices of Frank R. Cruz Glancy Prongay & Murray frequently acts as co-counsel or pursues parallel class-action lawsuits with The Law Offices of
+ 7 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.